An observational study in Chronic Pain, sponsored by Universidad Autonoma de Madrid. Status unknown at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-11-30.
Sponsored by Universidad Autonoma de Madrid · Observational
A case-control study will be conducted to analyze the differences in BDNF levels between patients with chronic pain and asymptomatic people.
Brain-derived neurotrophic factor (BDNF) is considered a biomarker of brain plasticity. Since different alterations in brain plasticity have been found in chronic pain patients, the investigators want to study whether there are differences at the molecular level in this population compared to an asymptomatic population in order to be able to accurately measure the impact of different physiotherapy interventions in an objective way.
2,999 studies on the registry are indexed under Chronic Pain; 706 are open to participants now.
This study's planned enrollment of 66 is below the median of 128 across 706 observational studies indexed under Chronic Pain.
Browse Chronic Pain studies →Universidad Autonoma de Madrid is the lead sponsor of 51 studies on the registry; 7 are open to participants now.
Counted across the registry records on this site, refreshed daily.
subjects will be selected if they have been suffering from musculoskeletal pain (not oncological) for at least 3 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
A blood draw is to be performed to analyze peripheral BDNF.
Genetic: BDNF analysis (Elisa KIT)
A blood draw is to be performed to analyze peripheral BDNF.
Genetic: BDNF analysis (Elisa KIT)
Analysis of peripheral BDNF will be performed
BDNF Levels
Brain Derived Neurotrophic Factor: Pierce NeutrAvidin-coated high-capacity plates (ThermoFisher Scientific; 15509) will incubate for two hours at RT with 200 µl of 14 µg/ml biotin-conjugated mAb-#1 diluted in phosphate buffer (0.1% Triton X-100 in 0.1 M phosphate buffer: 0.1 M KH2PO4 and 0.1 M Na2HPO4; pH 7.6). Plates will then washed three times with blocking buffer \[1% bovine serum albumin (BSA); Sigma A2153 in phosphate buffer\], followed by the addition of 150 µl phosphate buffer. A total of 50 µl of either standards or diluted samples (both in blocking buffer) will then added to the plate followed by incubation for 3 h at RT on a rotary shaker.
Time frame: 3 hours
Pain Intensity
Pain intensity assessed with the 100 mm Visual Analog Scale, in which the patient is asked about his or her pain level at that moment, with one side being "no pain" and the other extreme being "the worst pain imaginable"
Time frame: 3 hours
Plan to share: No
No publications or documents are linked to this record.
Started May 2023 (actual). Primary completion is estimated for Feb 2024, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Universidad Autonoma de Madrid